Abstract
Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscle. Metformin also has been shown to reduce cardiovascular events in randomized controlled trials; however, the underlying mechanism remains to be established. Recent preclinical and clinical studies have suggested that metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, but also has a direct anti-inflammatory action. Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor κB (NFκB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. This review summarizes the basic and clinical evidence of the anti-inflammatory action of metformin and discusses its clinical implication.
Keywords: AMPK, anti-inflammatory effect, biguanide, NFκB, type 2 diabetes.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect
Volume: 15 Issue: 3
Author(s): Yoshifumi Saisho
Affiliation:
Keywords: AMPK, anti-inflammatory effect, biguanide, NFκB, type 2 diabetes.
Abstract: Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscle. Metformin also has been shown to reduce cardiovascular events in randomized controlled trials; however, the underlying mechanism remains to be established. Recent preclinical and clinical studies have suggested that metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, but also has a direct anti-inflammatory action. Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor κB (NFκB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. This review summarizes the basic and clinical evidence of the anti-inflammatory action of metformin and discusses its clinical implication.
Export Options
About this article
Cite this article as:
Saisho Yoshifumi, Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (3) . https://dx.doi.org/10.2174/1871530315666150316124019
DOI https://dx.doi.org/10.2174/1871530315666150316124019 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Current Drug Targets Inflammation-Induced Thrombosis: Mechanisms, Disease Associations and Management
Current Pharmaceutical Design Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Overview of Hyperuricaemia and Gout
Current Pharmaceutical Design Antiphospholipid Syndrome as a Neurological Disease
Current Rheumatology Reviews Update on Childhood Brucellosis
Recent Patents on Anti-Infective Drug Discovery Extrapulmonary Tuberculosis- Its Management and Control
Current Drug Therapy Insulin-Degrading Enzyme: Structure-Function Relationship and its Possible Roles in Health and Disease
Current Pharmaceutical Design Role of Invariant Natural Killer T (iNKT) Cells in Systemic Lupus Erythematosus
Current Medicinal Chemistry Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design Rheumatoid Arthritis: Genetic Variants as Biomarkers of Cardiovascular Disease
Current Pharmaceutical Design Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Mechanisms of Corticosteroid Resistance in Severe Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Current Pharmaceutical Design Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry